Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Enrofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | HPGD | P15428 | 2/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | TOP2A | P11388 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enrofloxacin SCHEMBL29349852 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL17554684 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL149150 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL6742652 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL10741694 | 0.97 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL17554678 | 0.97 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL976909 | 0.97 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL9788077 | 0.97 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL8027963 | 0.97 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Enrofloxacin SCHEMBL16784595 | 0.97 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103768066-A | Quinolone pharmaceutical composition, and preparation and application methods thereof | LUOYANG HUIZHONG ANIMAL MEDICINE CO LTD | 2014-05-07 | — | — | CN | disclosed |
| US-7973022-B2 | Fluoroquinolone carboxylic acid salt compositions | IDEXX LABORATORIES, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| WO-2008094549-A1 | FLUOROQUINOLONE CARBOXYLIC ACID SALT COMPOSITIONS | IDEXX LABORATORIES INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20070203097-A1 | Fluoroquinolone carboxylic acid salt compositions | IDEXX LABORATORIES INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070197469-A1 | Fluoroquinolone carboxylic acid salt compositions | IDEXX LABORATORIES INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203097-A1 | Fluoroquinolone carboxylic acid salt compositions | SLC10A2, SLC10A1, SLC47A1 | KDM4E 3690/4885ALDH1A1 2243/4885LMNA 4066/4885 |
| US-20070197469-A1 | Fluoroquinolone carboxylic acid salt compositions | SLC10A2, SLC10A1, SLC47A1 | KDM4E 3690/4885ALDH1A1 2243/4885LMNA 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.